Creating a space for connection, knowledge, and hope is vital for the Inherited Retinal Disease (IRD) community. Kiora partnered with Vision Australia to host the IRD Breakfast Symposium—a gathering to inspire progress and share stories of resilience and hope.
Watch inspiring stories of Kiora trial patients with KIO-301, our innovative drug designed to restore functional vision in those with inherited retinal diseases (IRDs). KIO-301 offers hope for patients with IRDs who currently have no available treatments. The testimonials highlight significant improvements in their vision and quality of life.
The information contained in the content posted on this page was factually accurate on the date it was issued. Kiora assumes no duty to update the information to reflect subsequent developments. Readers of the news releases should not rely upon the information as current or accurate after their issuance dates.